News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients There was no reduction in CV death, but HF doctors are happy to gain another agent for use in HFmrEF/HFpEF patients. Michael O'Riordan September 01, 2024
Presentation NY Valves 2024 Real World TTVI Registries: Is There Concordance With the Randomized Trials? Presenter: Bassem M. Chehab June 07, 2024
Presentation NY Valves 2024 Transcatheter Tricuspid Valve Replacement - TRISCEND II Presenter: Raj Makkar June 07, 2024
Presentation EuroPCR 2024 Impact of valve type and anaesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI trial Presenter: Hans-Josef Feistritzer May 14, 2024
Presentation ACC 2024 Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC) Presenter: Rasha K. Al-Lamee April 08, 2024
News Conference News ESC 2024 New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower By Yael L. Maxwell September 04, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients By Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events By Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Trial Challenges Continuation of Oral Anticoagulants During TAVI By Todd Neale August 31, 2024
News Conference News ESC 2024 Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events By Caitlin E. Cox August 31, 2024